SIRO Clinpharm named Indian CRO of the Year 2012

Monday, October 1, 2012 09:20 AM

SIRO Clinpharm, a drug development solutions provider, has been awarded the 'Indian CRO of the Year 2012' by Frost & Sullivan, a global growth partnership and consulting firm.

The award was received by Gopakumar Menon, CEO, SIRO Clinpharm on behalf of the employees. "I am proud to receive this award as an ambassador of exceptional professionals across three continents, whose daily pursuit of excellence has resulted in SIRO Clinpharm receiving this award for two consecutive years," he said.

Ajaykumar Sharma, associate director of pharma and biotech, South Asia and Middle East, Frost & Sullivan, added, "With all the regulatory challenges which had taken off the sheen from the Indian CRO industry in the last few years, it is amazing to see a company repeating this feat for the second year in a row.”

The award is a testimony to SIRO Clinpharm's commitment in supporting its stakeholders through ethical, transparent and best-in-class services.

"As the Indian markets open to the western world, there are a number of challenges we face not just as a company but as an industry,” said Vatsal Shah, head of medical writing and pharmacovigilance, SIRO. “However, we have been able to convert these challenges into opportunities by ensuring process excellence, improving service delivery and focusing on training and development of our resources—thus, delivering a spectrum of services that is unique to the industry.”

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs